Author

L. Rivero-Nava

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:benchmarking· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Organism:rat· 1

Frequent Co-Authors

A. Singh· 2 shared D. Bresson· 2 shared H. Ji· 2 shared H. Zhou· 2 shared L. Kerwin· 2 shared R. Lim· 2 shared Y. Fu· 2 shared A. Garcia-Sastre· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

A. Singh

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants

J. A. Duty, T. A. Kraus, H. Zhou, Y. Zhang, N. Shaabani, S. Yildiz, N. Du, A. Singh, L. Miorin, D. Li, K. Stegman, S. I. Ophir, X. Cao, K. Atanasoff, R. Lim, , R. Allen

This paper identifies a broadly neutralizing antibody, STI-9167, effective against SARS-CoV-2 variants including Omicron and Omicron + R346K, and describes its development for clinical trials.

bioRxiv · Jan 19, 2022 · PreprintMicrobiology

Protective Effects of STI-2020 Antibody Delivered Post-Infection by the Intranasal or Intravenous Route in a Syrian Golden Hamster COVID-19 Model

Y. Fu, J. Maruyama, A. Singh, R. Lim, A. Ledesma, D. Lee, L. Rivero-Nava, J. Ko, I. Rivera, R. A. Sattler, J. T. Manning, L. Kerwin, H. Zhou, M. Brunswick, D. Bresson, , R. D. Allen

This study evaluates the efficacy of STI-2020 antibody delivered post-infection via intranasal or intravenous routes in a hamster model of COVID-19, showing reduced disease severity and duration.

bioRxiv · Oct 28, 2020 · PreprintMicrobiology